The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Barrett Esophagus

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Barrett Esophagus


High impact information on Barrett Esophagus


Chemical compound and disease context of Barrett Esophagus


Biological context of Barrett Esophagus


Anatomical context of Barrett Esophagus


Gene context of Barrett Esophagus


Analytical, diagnostic and therapeutic context of Barrett Esophagus


  1. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. Bani-Hani, K., Martin, I.G., Hardie, L.J., Mapstone, N., Briggs, J.A., Forman, D., Wild, C.P. J. Natl. Cancer Inst. (2000) [Pubmed]
  2. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Ormsby, A.H., Vaezi, M.F., Richter, J.E., Goldblum, J.R., Rice, T.W., Falk, G.W., Gramlich, T.L. Gastroenterology (2000) [Pubmed]
  3. Familial gastroesophageal reflux and development of Barrett's esophagus. Crabb, D.W., Berk, M.A., Hall, T.R., Conneally, P.M., Biegel, A.A., Lehman, G.A. Ann. Intern. Med. (1985) [Pubmed]
  4. Preventing death of Barrett's cancer: does frequent surveillance endoscopy do it? Sontag, S.J. Am. J. Med. (2001) [Pubmed]
  5. Barrett's esophagus in children. Diagnosis and management. Othersen, H.B., Ocampo, R.J., Parker, E.F., Smith, C.D., Tagge, E.P. Ann. Surg. (1993) [Pubmed]
  6. Ethanol abuse and Barrett's esophagus. Martini, G.A. N. Engl. J. Med. (1976) [Pubmed]
  7. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. Buttar, N.S., Wang, K.K., Anderson, M.A., Dierkhising, R.A., Pacifico, R.J., Krishnadath, K.K., Lutzke, L.S. J. Natl. Cancer Inst. (2002) [Pubmed]
  8. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. Galipeau, P.C., Prevo, L.J., Sanchez, C.A., Longton, G.M., Reid, B.J. J. Natl. Cancer Inst. (1999) [Pubmed]
  9. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Sharma, P., McQuaid, K., Dent, J., Fennerty, M.B., Sampliner, R., Spechler, S., Cameron, A., Corley, D., Falk, G., Goldblum, J., Hunter, J., Jankowski, J., Lundell, L., Reid, B., Shaheen, N.J., Sonnenberg, A., Wang, K., Weinstein, W. Gastroenterology (2004) [Pubmed]
  10. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Berenson, M.M., Johnson, T.D., Markowitz, N.R., Buchi, K.N., Samowitz, W.S. Gastroenterology (1993) [Pubmed]
  11. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gossner, L., Stolte, M., Sroka, R., Rick, K., May, A., Hahn, E.G., Ell, C. Gastroenterology (1998) [Pubmed]
  12. Pharmacotherapy of an ulcer in Barrett's esophagus: carbenoxalone and cimetidine. Thompson, W.G., Barr, R. Gastroenterology (1977) [Pubmed]
  13. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Kaur, B.S., Khamnehei, N., Iravani, M., Namburu, S.S., Lin, O., Triadafilopoulos, G. Gastroenterology (2002) [Pubmed]
  14. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. van Lieshout, E.M., Roelofs, H.M., Dekker, S., Mulder, C.J., Wobbes, T., Jansen, J.B., Peters, W.H. Cancer Res. (1999) [Pubmed]
  15. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Blount, P.L., Meltzer, S.J., Yin, J., Huang, Y., Krasna, M.J., Reid, B.J. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  16. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Galipeau, P.C., Cowan, D.S., Sanchez, C.A., Barrett, M.T., Emond, M.J., Levine, D.S., Rabinovitch, P.S., Reid, B.J. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  17. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Sirieix, P.S., O'Donovan, M., Brown, J., Save, V., Coleman, N., Fitzgerald, R.C. Clin. Cancer Res. (2003) [Pubmed]
  18. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Zou, H., Molina, J.R., Harrington, J.J., Osborn, N.K., Klatt, K.K., Romero, Y., Burgart, L.J., Ahlquist, D.A. Int. J. Cancer (2005) [Pubmed]
  19. Gastric proteases in Barrett's esophagus. Westerveld, B.D., Pals, G., Bosma, A., Defize, J., Pronk, J.C., Frants, R.R., Eriksson, A.W., Meuwissen, S.G. Gastroenterology (1987) [Pubmed]
  20. Evaluation of p53 mutations in premalignant esophageal lesions and esophageal adenocarcinoma using laser capture microdissection. Djalilvand, A., Pal, R., Goldman, H., Antonioli, D., Kocher, O. Mod. Pathol. (2004) [Pubmed]
  21. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Phillips, R.W., Frierson, H.F., Moskaluk, C.A. Am. J. Surg. Pathol. (2003) [Pubmed]
  22. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Buskens, C.J., Van Rees, B.P., Sivula, A., Reitsma, J.B., Haglund, C., Bosma, P.J., Offerhaus, G.J., Van Lanschot, J.J., Ristimäki, A. Gastroenterology (2002) [Pubmed]
  23. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Souza, R.F., Shewmake, K., Terada, L.S., Spechler, S.J. Gastroenterology (2002) [Pubmed]
  24. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Maley, C.C., Galipeau, P.C., Li, X., Sanchez, C.A., Paulson, T.G., Reid, B.J. Cancer Res. (2004) [Pubmed]
  25. Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Glickman, J.N., Shahsafaei, A., Odze, R.D. Am. J. Surg. Pathol. (2003) [Pubmed]
  26. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Abdalla, S.I., Lao-Sirieix, P., Novelli, M.R., Lovat, L.B., Sanderson, I.R., Fitzgerald, R.C. Clin. Cancer Res. (2004) [Pubmed]
  27. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Lieberman, D.A., Oehlke, M., Helfand, M. Am. J. Gastroenterol. (1997) [Pubmed]
  28. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Morris, C.D., Armstrong, G.R., Bigley, G., Green, H., Attwood, S.E. Am. J. Gastroenterol. (2001) [Pubmed]
  29. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Piazuelo, E., Jimenez, P., Lanas, A. Curr. Pharm. Des. (2003) [Pubmed]
WikiGenes - Universities